Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key metrics: revenue $263.7M vs. $238.1M expected, and gross margin 68.0% vs. 64.5%. Molecular profiling services revenue surged 55% YoY, driven by strong clinical volume and ASP improvements. Positive Adjusted EBITDA of $55.7M and free cash flow of $6.4M demonstrate a sharp turn toward profitability, while FY26 revenue guidance was raised to $1.03B-$1.04B, exceeding the prior market outlook.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Caris Life Sciences(CAI) the Revenue is 263.71 M (+45.38%), Beat estimate;the EBIT is 26.93 M (+249.7%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.26B45.38%
0.24B31.25%
+0.03B14.13%
EBITExceed expectations
0.03B249.68%
0.01B154.38%
+0.02B95.30%
EPS
TBA--
0.0065100.58%
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf